Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

Matthew T Seymour; Sarah R Brown; Gary Middleton; Timothy Maughan; Susan Richman; Stephen Gwyther; Catherine Lowe; Jennifer F Seligmann; Jonathan Wadsley; Nick Maisey; Ian Chau; Mark Hill; Lesley Dawson; Stephen Falk; Ann O'Callaghan; Kim Benstead; Philip Chambers; Alfred Oliver; Helen Marshall; Vicky Napp; Phil Quirke

doi:10.1016/S1470-2045(13)70163-3

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

Matthew T Seymour
, Sarah R Brown
, Gary Middleton
, Timothy Maughan
, Susan Richman
, Stephen Gwyther
, Catherine Lowe
, Jennifer F Seligmann
, Jonathan Wadsley
, Nick Maisey
, Ian Chau
, Mark Hill
, Lesley Dawson
, Stephen Falk
, Ann O'Callaghan
, Kim Benstead
, Philip Chambers
, Alfred Oliver
, Helen Marshall
, Vicky Napp

Phil Quirke

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

270 Citations (Scopus)

Abstract

Therapeutic antibodies targeting EGFR have activity in advanced colorectal cancer, but results from clinical trials are inconsistent and the population in which most benefit is derived is uncertain. Our aim was to assess the addition of panitumumab to irinotecan in pretreated advanced colorectal cancer.

Original language	English
Pages (from-to)	749-59
Number of pages	11
Journal	The Lancet Oncology
Volume	14
Issue number	8
DOIs	https://doi.org/10.1016/S1470-2045(13)70163-3
Publication status	Published - Jul 2013

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S1470-2045(13)70163-3

Cite this

Seymour, M. T., Brown, S. R., Middleton, G., Maughan, T., Richman, S., Gwyther, S., Lowe, C., Seligmann, J. F., Wadsley, J., Maisey, N., Chau, I., Hill, M., Dawson, L., Falk, S., O'Callaghan, A., Benstead, K., Chambers, P., Oliver, A., Marshall, H., ... Quirke, P. (2013). Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. The Lancet Oncology, 14(8), 749-59. https://doi.org/10.1016/S1470-2045(13)70163-3

@article{d83d568d44684e118fb15a7e80d0d681,

title = "Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial",

abstract = "Therapeutic antibodies targeting EGFR have activity in advanced colorectal cancer, but results from clinical trials are inconsistent and the population in which most benefit is derived is uncertain. Our aim was to assess the addition of panitumumab to irinotecan in pretreated advanced colorectal cancer.",

author = "Seymour, \{Matthew T\} and Brown, \{Sarah R\} and Gary Middleton and Timothy Maughan and Susan Richman and Stephen Gwyther and Catherine Lowe and Seligmann, \{Jennifer F\} and Jonathan Wadsley and Nick Maisey and Ian Chau and Mark Hill and Lesley Dawson and Stephen Falk and Ann O'Callaghan and Kim Benstead and Philip Chambers and Alfred Oliver and Helen Marshall and Vicky Napp and Phil Quirke",

year = "2013",

month = jul,

doi = "10.1016/S1470-2045(13)70163-3",

language = "English",

volume = "14",

pages = "749--59",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier",

number = "8",

}

Seymour, MT, Brown, SR, Middleton, G, Maughan, T, Richman, S, Gwyther, S, Lowe, C, Seligmann, JF, Wadsley, J, Maisey, N, Chau, I, Hill, M, Dawson, L, Falk, S, O'Callaghan, A, Benstead, K, Chambers, P, Oliver, A, Marshall, H, Napp, V & Quirke, P 2013, 'Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial', The Lancet Oncology, vol. 14, no. 8, pp. 749-59. https://doi.org/10.1016/S1470-2045(13)70163-3

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. / Seymour, Matthew T; Brown, Sarah R; Middleton, Gary et al.
In: The Lancet Oncology, Vol. 14, No. 8, 07.2013, p. 749-59.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO)

T2 - a prospectively stratified randomised trial

AU - Seymour, Matthew T

AU - Brown, Sarah R

AU - Middleton, Gary

AU - Maughan, Timothy

AU - Richman, Susan

AU - Gwyther, Stephen

AU - Lowe, Catherine

AU - Seligmann, Jennifer F

AU - Wadsley, Jonathan

AU - Maisey, Nick

AU - Chau, Ian

AU - Hill, Mark

AU - Dawson, Lesley

AU - Falk, Stephen

AU - O'Callaghan, Ann

AU - Benstead, Kim

AU - Chambers, Philip

AU - Oliver, Alfred

AU - Marshall, Helen

AU - Napp, Vicky

AU - Quirke, Phil

PY - 2013/7

Y1 - 2013/7

N2 - Therapeutic antibodies targeting EGFR have activity in advanced colorectal cancer, but results from clinical trials are inconsistent and the population in which most benefit is derived is uncertain. Our aim was to assess the addition of panitumumab to irinotecan in pretreated advanced colorectal cancer.

AB - Therapeutic antibodies targeting EGFR have activity in advanced colorectal cancer, but results from clinical trials are inconsistent and the population in which most benefit is derived is uncertain. Our aim was to assess the addition of panitumumab to irinotecan in pretreated advanced colorectal cancer.

U2 - 10.1016/S1470-2045(13)70163-3

DO - 10.1016/S1470-2045(13)70163-3

M3 - Article

C2 - 23725851

SN - 1470-2045

VL - 14

SP - 749

EP - 759

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 8

ER -

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this